TUCIDINOSTAT for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where TUCIDINOSTAT was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for TUCIDINOSTAT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 85 | 33.9% | 4 | 24 |
| Disease progression | 37 | 14.7% | 19 | 3 |
| Anaemia | 33 | 13.2% | 5 | 4 |
| Pneumonia | 30 | 12.0% | 13 | 5 |
| Off label use | 28 | 11.2% | 7 | 10 |
| Platelet count decreased | 24 | 9.6% | 3 | 11 |
| Nausea | 22 | 8.8% | 5 | 3 |
| White blood cell count decreased | 21 | 8.4% | 1 | 8 |
| Drug ineffective | 19 | 7.6% | 8 | 2 |
| Treatment failure | 16 | 6.4% | 12 | 4 |
| Neutrophil count decreased | 15 | 6.0% | 0 | 4 |
| Thrombocytopenia | 15 | 6.0% | 4 | 3 |
| Febrile neutropenia | 13 | 5.2% | 2 | 0 |
| Pyrexia | 13 | 5.2% | 1 | 5 |
| Hypokalaemia | 12 | 4.8% | 1 | 4 |
Other Indications for TUCIDINOSTAT
Diffuse large b-cell lymphoma (63)
Acute myeloid leukaemia (39)
Peripheral t-cell lymphoma unspecified (17)
Chemotherapy (12)
Angioimmunoblastic t-cell lymphoma (7)
Plasma cell myeloma (7)
T-cell lymphoma (6)
Acute myeloid leukaemia refractory (5)
Cutaneous t-cell lymphoma (5)
Lymphoma (5)
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
POLATUZUMAB VEDOTIN-PIIQ (158)
GEMCITABINE (147)
LENALIDOMIDE (143)